WHO Grants Pre-Qualification to GC Biopharma’s Revolutionary BARYCELA Treatment

GC Biopharma, a South Korean biopharmaceutical leader, is thrilled to announce that its varicella vaccine, BARYCELA, has been prequalified by the World Health Organization (WHO). This milestone marks a major success for GC Biopharma, as it is a critical step in ensuring the vaccine’s availability to those in need around the world.

GC Biopharma has achieved yet another milestone with the announcement of the World Health Organization’s (WHO) prequalification decision for BARYCELA, making it eligible for procurement by UN agencies, including the Pan American Health Organization (PAHO). With this, BARYCELA joins the ranks of H1N1 pandemic and seasonal influenza vaccines as the third PQ vaccine in GC Biopharma’s portfolio, enabling it to be used in national immunization programs.

BARYCELA is a groundbreaking live attenuated varicella virus vaccine, containing MAV/06 strain, a virus that has been exclusively and carefully attenuated by GC Biopharma. This new, improved vaccine not only contains a higher amount of virus, but boasts higher levels of product stability and immunogenicity! This remarkable vaccine has been proven to be non-inferior in safety to “VARIVAX”, a prequalified vaccine already on the market, making it an exciting new development in the world of healthcare.

BARYCELA is the world’s only varicella vaccine produced without antibiotics, produced in a state-of-the-art aseptic condition from cell culture and virus infection right through to purification. With an advanced production process like this, you can be sure that BARYCELA delivers the highest quality protection against varicella.

The MAV/06 strain has taken a big step forward, as it has been deemed worthy of prequalification by the World Health Organisation. This decision marks a milestone in its journey towards being registered in the esteemed WHO Technical Report Series (TRS), joining the already-listed OKA strain.

BGC Biopharma is looking to take its varicella vaccine, Suduvax, to the global stage with BARYCELA. By leveraging its existing global supply network, the company hopes to make a lasting impact on the international healthcare landscape.

EC Huh, Ph. D., President of GC Biopharma, believes that BARYCELA will play an essential role in reducing the global social and economic burden of varicella outbreaks. He is confident that this new vaccine will have a positive impact on the world.

Suduvax, developed by GC Biopharma in 1993, is not only the first varicella vaccine to be developed in Korea, but also the second of its kind in the world. Over the past three decades, its safety and efficacy have been proven with the sale of over 28 million doses of the vaccine across the globe through organisations such as the Pan American Health Organization (PAHO).

About GC Biopharma

GC Biopharma is a world leader in the production of life-saving and life-sustaining protein therapeutics and vaccines. Since its founding in Yongin, South Korea more than fifty years ago, GC Biopharma has earned a reputation for providing high-quality healthcare solutions to people around the world. The company’s commitment to quality is evident in the life-saving treatments and vaccines it produces, giving its customers access to the best possible treatments.

Leave a Comment